NeoGenomics (NEO) Competitors $10.05 -0.23 (-2.24%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$10.03 -0.02 (-0.20%) As of 10/17/2025 05:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NEO vs. FTDR, DGNX, DLO, WSC, HRI, HNGE, CARG, WNS, ATHM, and RELYShould you be buying NeoGenomics stock or one of its competitors? The main competitors of NeoGenomics include Frontdoor (FTDR), Diginex (DGNX), DLocal (DLO), WillScot (WSC), Herc (HRI), Hinge Health (HNGE), CarGurus (CARG), WNS (WNS), Autohome (ATHM), and Remitly Global (RELY). These companies are all part of the "business services" industry. NeoGenomics vs. Its Competitors Frontdoor Diginex DLocal WillScot Herc Hinge Health CarGurus WNS Autohome Remitly Global Frontdoor (NASDAQ:FTDR) and NeoGenomics (NASDAQ:NEO) are both business services companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership. Which has preferable earnings & valuation, FTDR or NEO? Frontdoor has higher revenue and earnings than NeoGenomics. NeoGenomics is trading at a lower price-to-earnings ratio than Frontdoor, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFrontdoor$1.84B2.60$235M$3.3919.44NeoGenomics$660.57M1.97-$78.73M-$0.81-12.41 Do analysts rate FTDR or NEO? Frontdoor currently has a consensus target price of $59.75, suggesting a potential downside of 9.33%. NeoGenomics has a consensus target price of $12.56, suggesting a potential upside of 24.93%. Given NeoGenomics' stronger consensus rating and higher probable upside, analysts clearly believe NeoGenomics is more favorable than Frontdoor.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Frontdoor 1 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17NeoGenomics 1 Sell rating(s) 8 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.38 Is FTDR or NEO more profitable? Frontdoor has a net margin of 13.07% compared to NeoGenomics' net margin of -15.10%. Frontdoor's return on equity of 125.21% beat NeoGenomics' return on equity.Company Net Margins Return on Equity Return on Assets Frontdoor13.07% 125.21% 15.65% NeoGenomics -15.10%-2.72%-1.54% Does the media refer more to FTDR or NEO? In the previous week, Frontdoor had 3 more articles in the media than NeoGenomics. MarketBeat recorded 5 mentions for Frontdoor and 2 mentions for NeoGenomics. Frontdoor's average media sentiment score of 1.00 beat NeoGenomics' score of 0.55 indicating that Frontdoor is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Frontdoor 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NeoGenomics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals have more ownership in FTDR or NEO? 98.5% of NeoGenomics shares are held by institutional investors. 1.5% of Frontdoor shares are held by company insiders. Comparatively, 2.4% of NeoGenomics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more volatility & risk, FTDR or NEO? Frontdoor has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500. Comparatively, NeoGenomics has a beta of 1.61, indicating that its share price is 61% more volatile than the S&P 500. SummaryFrontdoor beats NeoGenomics on 10 of the 16 factors compared between the two stocks. Get NeoGenomics News Delivered to You Automatically Sign up to receive the latest news and ratings for NEO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NEO vs. The Competition Export to ExcelMetricNeoGenomicsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.33B$3.40B$6.11B$10.51BDividend YieldN/A2.29%5.73%4.81%P/E Ratio-12.4122.4484.5227.09Price / Sales1.97477.80607.37219.49Price / Cash23.4346.5937.1661.22Price / Book1.4310.4112.246.52Net Income-$78.73M-$52.47M$3.32B$276.75M7 Day Performance10.44%2.32%1.25%2.00%1 Month Performance16.59%11.14%6.28%2.26%1 Year Performance-25.88%11.15%59.92%35.58% NeoGenomics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NEONeoGenomics2.9062 of 5 stars$10.05-2.2%$12.56+24.9%-25.6%$1.33B$660.57M-12.412,200News CoverageFTDRFrontdoor3.4899 of 5 stars$65.20+1.0%$59.75-8.4%+25.5%$4.70B$1.84B19.232,120Positive NewsDGNXDiginexN/A$25.70+3.1%N/AN/A$4.59BN/A0.0021Short Interest ↓Gap DownDLODLocal2.8862 of 5 stars$14.20+4.3%$14.00-1.4%+67.9%$4.25B$745.97M29.581,095News CoverageAnalyst UpgradeGap DownWSCWillScot4.6375 of 5 stars$21.75+0.7%$32.13+47.7%-42.4%$3.93B$2.40B36.254,500News CoverageHRIHerc3.562 of 5 stars$120.51+2.3%$149.20+23.8%-27.7%$3.91B$3.57B140.137,600Analyst ForecastHNGEHinge HealthN/A$50.39+1.2%$57.47+14.0%N/A$3.91BN/A0.001,514CARGCarGurus3.7774 of 5 stars$33.99+1.5%$38.79+14.1%+11.0%$3.33B$894.38M27.631,282Analyst ForecastInsider TradeWNSWNS1.7741 of 5 stars$76.30flat$67.43-11.6%+71.9%$3.27B$1.31B21.2564,505News CoverageTrading HaltedATHMAutohome3.7011 of 5 stars$26.77+1.0%$36.00+34.5%-5.6%$3.10B$964.42M15.754,415Positive NewsRELYRemitly Global3.4255 of 5 stars$14.85-0.9%$27.25+83.5%+8.1%$3.09B$1.26B247.542,800Insider Trade Related Companies and Tools Related Companies Frontdoor Alternatives Diginex Alternatives DLocal Alternatives WillScot Alternatives Herc Alternatives Hinge Health Alternatives CarGurus Alternatives WNS Alternatives Autohome Alternatives Remitly Global Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NEO) was last updated on 10/18/2025 by MarketBeat.com Staff From Our PartnersNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredTrump Issues Surprise Emergency OrderIs This Stock the 'Next Nvidia'? Billionaire Warren Buffett has been loading up on millions of shares of th...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeoGenomics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeoGenomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
